Sino Biopharmaceutical Limited

Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3

Retrieved on: 
Thursday, February 15, 2024

Frédéric Cren, Chairman, Chief Executive Officer and cofounder of Inventiva, stated: “2023 has been an eventful year for the company.

Key Points: 
  • Frédéric Cren, Chairman, Chief Executive Officer and cofounder of Inventiva, stated: “2023 has been an eventful year for the company.
  • This allowed us to draw down the second tranche of €25 million of the €50 million EIB loan in January 2024.
  • We have advanced our pivotal NATiV3 Phase III clinical trial with lanifibranor in NASH after the implementation of the revised study design in early 2023, with 913 patients randomized to date.
  • An adverse event of elevated aminotransferases has been reported in a patient enrolled in the trial following a scheduled visit.

Inventiva reports 2023 Third Quarter Financial Information¹

Retrieved on: 
Tuesday, November 21, 2023

Net cash used in operating activities amounted to (€69.0) million in the first nine months of 2023, compared to (€40.1) million for the same period in 2022.

Key Points: 
  • Net cash used in operating activities amounted to (€69.0) million in the first nine months of 2023, compared to (€40.1) million for the same period in 2022.
  • R&D expenses for the first nine months of 2023 were up 86 % compared to the same period in 2022.
  • The Company’s revenues for the first nine months of 2023 amounted to €1.9 million, stable from the first six months of 2023, compared to €0.1 million for the same period in 2022.
  • Inventiva has exercised the option to acquire 30% of the shares Hepalys Pharma for the price of 300 yen.

Sino Biopharmaceutical (1177.HK) Announces 2023 Interim Results

Retrieved on: 
Friday, August 25, 2023

HONG KONG, Aug 25, 2023 - (ACN Newswire) - Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading innovation-driven pharmaceutical conglomerate in the PRC, has announced its unaudited interim results for the six months ended 30 June 2023 (the "Period").

Key Points: 
  • HONG KONG, Aug 25, 2023 - (ACN Newswire) - Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading innovation-driven pharmaceutical conglomerate in the PRC, has announced its unaudited interim results for the six months ended 30 June 2023 (the "Period").
  • In the first half of 2023, two innovative products were launched to market and two biosimilar drugs received marketing approval.
  • -- Annike (Penpulimab monoclonal antibody) injection was approved in January 2023 for treating, in combination with chemotherapy, first-line locally advanced or metastatic squamous non-small cell lung cancer.
  • -- Yilishu (Efbemalenograstim alpha) injection was approved in May 2023 for the prevention and treatment of neutropenia in cancer patients taking chemotherapy drugs.

Techdow USA and CTTQ Pharma Announce Collaboration Agreement and Launch of Fosaprepitant for Injection

Retrieved on: 
Tuesday, August 22, 2023

Techdow USA Inc. (“Techdow USA”), a wholly owned subsidiary of Hepalink USA Inc., and Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (“CTTQ”), an integrated company engaged in the Development, Manufacturing and Licensing of pharmaceuticals, are pleased to announce the signing of a Licensing, Supply and Distribution agreement regarding the launch of Fosaprepitant for Injection, the therapeutic generic equivalent of EMEND® (fosaprepitant) for injection in the US market.

Key Points: 
  • Techdow USA Inc. (“Techdow USA”), a wholly owned subsidiary of Hepalink USA Inc., and Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (“CTTQ”), an integrated company engaged in the Development, Manufacturing and Licensing of pharmaceuticals, are pleased to announce the signing of a Licensing, Supply and Distribution agreement regarding the launch of Fosaprepitant for Injection, the therapeutic generic equivalent of EMEND® (fosaprepitant) for injection in the US market.
  • Fosaprepitant for Injection had US brand and generic sales of approximately $35 million, according to IQVIA Health for the 12 months ending June, 2023.
  • Both the API and drug product will be manufactured by CTTQ and the ANDA product will be sold under the Techdow USA Label.
  • Techdow USA continuously explores opportunities to expand their product portfolio and pipeline to better serve patients and customer needs.

China Cancer Antibodies Market Trends & Clinical Trials Insight Report 2023: Clinical Trials Insight By Phase, Indication, Location, Companies, Licensee, Mono/Combination Therapy Approach - ResearchAndMarkets.com

Retrieved on: 
Monday, June 5, 2023

The "China Cancer Antibodies Market Trends & Clinical Trials Insight 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "China Cancer Antibodies Market Trends & Clinical Trials Insight 2023" report has been added to ResearchAndMarkets.com's offering.
  • The current antibodies pipeline in China is still in the expansion phase as both domestic and international drug developers are continuously foraying into the market.
  • At present, multiple cancers are dominating the antibody clinical trials landscape in China similar to other developed pharmaceutical markets.
  • Clinical Trials Insight By Phase, Indication, Location, Companies, Licensee, Mono/Combination Therapy Approach

invoX Pharma Increases Investment in pHion Therapeutics to Further Develop Next Generation of mRNA Vaccines

Retrieved on: 
Thursday, June 1, 2023

invoX Pharma Limited (“invoX”), a U.K.-based wholly-owned subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”) (HKEX 1177 HK) with an advancing pipeline of innovative products, today announced that it has completed a second tranche of investment in pHion Therapeutics (“pHion”), a next-generation mRNA vaccine company.

Key Points: 
  • invoX Pharma Limited (“invoX”), a U.K.-based wholly-owned subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”) (HKEX 1177 HK) with an advancing pipeline of innovative products, today announced that it has completed a second tranche of investment in pHion Therapeutics (“pHion”), a next-generation mRNA vaccine company.
  • The company’s proprietary RALA platform can deliver anionic molecules such as mRNA and saRNA in a stealth-like way, evading detection, to generate a potent antigen-specific CD8+ T-cell response.
  • Prof. Helen McCarthy, Chief Executive Officer and Founder of pHion, said:
    “At pHion Therapeutics, it is our mission to pioneer next generation, first-in-class vaccines for infectious disease and oncology through stealth-like delivery of mRNA.
  • We look forward to seeing PTX_V1 reach the clinic and supporting this program into the next stages of its development.”

Inventiva announces that its partner Sino Biopharm received IND approval from the NMPA to initiate clinical trial with lanifibranor in China

Retrieved on: 
Thursday, May 25, 2023

Frederic Cren, CEO and cofounder of Inventiva, stated: “We are extremely pleased by this positive feedback from the NMPA, which allows our lead compound to advance into a Phase III clinical trial in NASH in mainland China.

Key Points: 
  • Frederic Cren, CEO and cofounder of Inventiva, stated: “We are extremely pleased by this positive feedback from the NMPA, which allows our lead compound to advance into a Phase III clinical trial in NASH in mainland China.
  • This is an important milestone for us and our partner Sino Biopharm, and brings new opportunities for patients affected by NASH in China to participate in the global NATiV3 Phase III clinical trial.
  • We are looking to successfully develop lanifibranor with Sino Biopharm and potentially commercialize in China the first oral treatment for patients with NASH.”
    Philip Duong, Head of Overseas BD & Alliance, Sino Biopharm: “We are delighted to have received the IND approval from the Chinese NMPA.
  • CTTQ will be responsible for all costs linked to lanifibranor development in China.

Sino Biopharm (1177.HK) Announces 2022 Annual Results

Retrieved on: 
Friday, March 31, 2023

HONG KONG, Mar 31, 2023 - (ACN Newswire) - Sino Biopharmaceutical Limited ("Sino Biopharm" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading innovation-driven pharmaceutical conglomerate in the PRC, has announced its audited financial results for the year ended 31 December 2022.

Key Points: 
  • HONG KONG, Mar 31, 2023 - (ACN Newswire) - Sino Biopharmaceutical Limited ("Sino Biopharm" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading innovation-driven pharmaceutical conglomerate in the PRC, has announced its audited financial results for the year ended 31 December 2022.
  • To date, the product has been approved for two indications: third-line classic Hodgkin's lymphoma and first-line squamous non-small cell lung cancer.
  • Phase III clinical trials have been completed with marketing applications submitted in China and the United States.
  • With its strong oncology sales team, Sino Biopharm is confident in a smooth launch and rapid market penetration of the product.

Inventiva reports its 2022 full-year results

Retrieved on: 
Wednesday, March 29, 2023

Frédéric Cren, Chairman, CEO and cofounder of Inventiva, stated: “2022 has been a successful year for Inventiva in many ways.

Key Points: 
  • Frédéric Cren, Chairman, CEO and cofounder of Inventiva, stated: “2022 has been a successful year for Inventiva in many ways.
  • Net cash used in operating activities amounted to (€44.9) million for the full year 2022, compared to (€47.6) million in 2021.
  • Net cash generated from financing activities amounted to €37.3 million for the full year 2022 compared to €25.4 million for 2021.
  • Income tax amounted to €0 million for the 2022 fiscal year, compared to (€0.4) million for 2021.

InvoX Pharma’s F-star Announces Licence Agreement With Takeda for Second Novel Next-Generation Immuno-Oncology Bispecific Antibody

Retrieved on: 
Wednesday, March 22, 2023

InvoX Pharma Limited (“invoX”), a U.K.-based wholly-owned subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”) (HKEX 1177 HK) with an advancing pipeline of innovative products, today announces that F-star, an invoX company, has entered into a second licence agreement with Takeda for a novel next-generation immuno-oncology bispecific antibody.

Key Points: 
  • InvoX Pharma Limited (“invoX”), a U.K.-based wholly-owned subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”) (HKEX 1177 HK) with an advancing pipeline of innovative products, today announces that F-star, an invoX company, has entered into a second licence agreement with Takeda for a novel next-generation immuno-oncology bispecific antibody.
  • Under the terms of the licence agreement, F-star will grant Takeda a worldwide, exclusive royalty-bearing licence to research, develop, and commercialize a bispecific antibody directed towards an undisclosed immuno-oncology target using F-star’s proprietary Fcab™ and mAb2™ platforms.
  • This licence agreement represents the second option that Takeda has exercised under an evaluation and licence agreement with F-star that was entered into in July 2021.
  • F-star and Takeda entered into a licence agreement for a different bispecific antibody in July 2022.